...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer Biology >Clinical outcomes of Basal versus Non-Basal clone in Triple Negative Breast Cancer patients
【24h】

Clinical outcomes of Basal versus Non-Basal clone in Triple Negative Breast Cancer patients

机译：三阴性乳腺癌患者基础克隆与非基础克隆的临床结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: The aim of this study was to investigate the co-expression of basal markers in triple negative breast cancer (TNBC) patients and to assess its impact on survival, disease free and overall (DFS and OS). Methods: This study was conducted on 51 patients with TNBC subtype who were treated from January 2009 until March 2013. All patients were evaluated by immunohistochemical analysis for steroid hormones (ER, PR, HER.2 & Ki 67) and basal markers (CK5/6 & EGFR). They were subsequently subdivided into two groups: basal group (n=24, 47.1%) and non-basal group (n=27, 52.9%). Basal markers expression were correlated with clinicopathological factors analyzed using the Chi square test and survival (DFS and OS) using kaplan -meier. Cox proportional hazard model was used to assess variables in multivariate analysis. Results: The mean age of all patients was 45.6 years. The median follow-up period was 27 months. Basal group showed 20/24 patients (83.3%) with positive CK5/6, 21/24 patients (87.5%) with positive EGFR and 17/24 patients (70.8%) with positive both CK5/6 and EGFR. For recurrent event, 23/24 patients (95.8%) in basal group versus 10/27 patients (37%) in non-basal group, P=0.001. For death event, 19/24 patients (79.2%) in basal group versus 5/27 patients (18.5%) in non-basal group, P=0.001. There were significant worsened survival with basal group compared to non-basal group (DFS and OS), P≤0.001. There was negative significant impact of all prognostic factors on DFS in basal group. Multivariate analysis revealed that rate of metastases (95% C1 (1.603-3.370), OR= 2.307, P=0.001), high grade (95% C1 (1.631-8.52), OR= 3.729, P=0.002) and positive Ki 67 14% (95% C1 (0.029-0.634), OR=0.135, P=0.011) had retained their independent prognostic value for DFS with basal-like tumors. Conclusion : TNBC basal-like is a poor prognostic factor for DFS and OS, need more trials to support this prognostic power and allow the use of effective specific therapeutic targets to improve future image of this subtype.
机译：目的：本研究的目的是研究三阴性乳腺癌（TNBC）患者中基础标志物的共表达，并评估其对生存，无病和总体（DFS和OS）的影响。方法：本研究对2009年1月至2013年3月接受治疗的51例TNBC亚型患者进行了研究。所有患者均通过免疫组化分析评估了类固醇激素（ER，PR，HER.2和Ki 67）和基础标志物（CK5 / 6＆EGFR）。随后将它们分为两组：基础组（n = 24，47.1％）和非基础组（n = 27，52.9％）。基础标志物表达与使用卡方检验分析的临床病理因素相关，并通过kaplan -meier评估生存率（DFS和OS）。使用Cox比例风险模型评估多变量分析中的变量。结果：所有患者的平均年龄为45.6岁。中位随访期为27个月。基础组显示20/24例（83.3％）CK5 / 6阳性，21/24例（87.5％）EGFR阳性，17/24例（70.8％）CK5 / 6和EGFR阳性。对于复发事件，基础组为23/24例患者（95.8％），而非基础组为10/27例患者（37％），P = 0.001。对于死亡事件，基础组为19/24例患者（79.2％），而非基础组为5/27例患者（18.5％），P = 0.001。与非基础组（DFS和OS）相比，基础组的生存期显着恶化，P≤0.001。基础组所有预后因素均对DFS有负面影响。多变量分析显示转移率（95％C1（1.603-3.370），OR = 2.307，P = 0.001），高转移（95％C1（1.631-8.52），OR = 3.729，P = 0.002）和Ki 67阳性> 14％（95％C1（0.029-0.634），OR = 0.135，P = 0.011）保留了基底样肿瘤对DFS的独立预后价值。结论：TNBC基底样是DFS和OS的不良预后因素，需要更多试验以支持该预后力，并允许使用有效的特异性治疗靶标来改善该亚型的未来形象。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号